Improving the outcome of bloodstream infection in patients with hematological malignancies: looking beyond antibiotics

References

• Attman E AJ, Sinisalo M, Vuento R, et al. Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with haematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital. Leuk Lymphoma 2015;56:3372–3379.
   Web of Science ®Google Scholar
• Cherif H, Kronvall G, Bjorkholm M, et al. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 2003;4:420–426.
   PubMedGoogle Scholar
• Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103–1110.
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247–259.
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Worth LJ, Thursky KA, et al. The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol 2015;79:195–207.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006;50:498–504.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infectious Dis 2014;27:200–210.
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Lesse AJ, Hahn T, et al. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infect Control Hosp Epidemiol 2011;32:490–496.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010;65: 333–341.
   PubMed Web of Science ®Google Scholar
• Paul M, Gafter-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988–2004. Israel Med Ass J 2007;9:424–429.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infection 2015;21:337–343.
   PubMed Web of Science ®Google Scholar
• Velasco E, Byington R, Martins CA, et al. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infectious Dis 2003;22:137–143.
   PubMed Web of Science ®Google Scholar
• Velasco E, Soares M, Byington R, et al. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients. Eur J Clin Microbiol 2004;23:596–602.
   Google Scholar
• Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681–687.
   PubMed Web of Science ®Google Scholar
• Andersen VD, Jensen VF, Vigre H, et al. The use of third and fourth generation cephalosporins affects the occurrence of extended-spectrum cephalosporinase-producing Escherichia coli in Danish pig herds. Vet J 2015;204:345–350.
   PubMed Web of Science ®Google Scholar
• Huh K, Kang CI, Kim J, et al. Risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporin-resistant Enterobacter species in adults with cancer. Diagnost Microbiol Infectious Dis 2014;78:172–177.
   PubMed Web of Science ®Google Scholar
• Lee SO, Lee ES, Park SY, et al. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004;25:832–837.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Reilly M, Andresen D, et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Internal Med J 2011;41:90–101.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infectious Dis 2011;52:e56–93.
   PubMed Web of Science ®Google Scholar
• Bate J, Gibson F, Johnson E, et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Arch Dis Childh Educat Pract 2013;98:73–75.
   Google Scholar
• de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(Suppl. 5):v252–256.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013;21:1487–1495.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Thursky KA. Outpatient therapy for fever and neutropenia is safe but implementation is the key. J Clin Oncol 2013;31:1128–1129.
   PubMed Web of Science ®Google Scholar
• Velasco E, Byington R, Martins CA, et al. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur J Clin Microbiol Infectious Dis 2006;25:1–7.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013;98:1826–1835.
   PubMed Web of Science ®Google Scholar
• Briegel J, Mohnle P, Surviving Sepsis C. [International guidelines of the Surviving Sepsis Campaign : update 2012]. Der Anaesthesist 2013;62:304–309.
   PubMed Web of Science ®Google Scholar
• Commission NCE. Sepsis Kills Program. Accessed 15 May 2015 from: http://www.cec.health.nsw.gov.au/programs/sepsis
   Google Scholar
• Penack O, Becker C, Buchheidt D, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol 2014;93:1083–1095.
   PubMed Web of Science ®Google Scholar
• Levy MM, Rhodes A, Phillips GS, et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Crit Care Med 2015;43:3–12.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31:794–810.
   PubMed Web of Science ®Google Scholar
• Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Services Res 2014;14:162.
   PubMed Web of Science ®Google Scholar
• Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother 2014;58:3799–803.
   PubMed Web of Science ®Google Scholar
• Yurkova I, Wolf L. Under-triage as a significant factor affecting transfer time between the emergency department and the intensive care unit. J Emerg Nursing 2011;37:491–496.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Casari S, Bracchi F, et al. Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infectious Dis 2010;42:324–332.
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Chemaly RF. Infection control practices in patients with hematological malignancies and multidrug-resistant organisms: special considerations and challenges. Clin Lymphoma Myeloma Leuk 2014;14(Suppl.):S104–110.
   PubMed Web of Science ®Google Scholar
• Worth LJ, Thursky KA, Seymour JF, et al. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Hematol 2007;79:226–233.
   PubMed Web of Science ®Google Scholar
• Yeo CL, Chan DS, Earnest A, et al. Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in Singapore. Eur J Clin Microbiol Infectious Dis 2012;31:583–590.
   PubMed Web of Science ®Google Scholar
• Yeo CL, Wu JE, Chung GW, et al. Specialist trainees on rotation cannot replace dedicated consultant clinicians for antimicrobial stewardship of specialty disciplines. Antimicrob Resist Infect Control 2012;1:36.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infectious Dis 2012;25:107–115.
   PubMed Web of Science ®Google Scholar
• Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012;67:2988–2996.
   PubMed Web of Science ®Google Scholar
• Lingaratnam S, Thursky KA, Slavin MA. Fluoroquinolone prophylaxis: a word of caution. Leuk Lymphoma 2011;52:5–6.
   PubMed Web of Science ®Google Scholar
• Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010;116:967–973.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Q, Ling Y, et al. Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer. BMC Cancer 2015;15:42.
   PubMed Web of Science ®Google Scholar
• Honda H, Krauss MJ, Jones JC, et al. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010;123:631–637.
   PubMed Web of Science ®Google Scholar
• Bai AD, Showler A, Burry L, et al. Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study. Clin Infectious Dis 2015;60:1451–1461.
   PubMed Web of Science ®Google Scholar
• Granwehr BP, Kontoyiannis DP. The impact of infectious diseases consultation on oncology practice. Curr Opin Oncol 2013;25:353–359.
   PubMed Web of Science ®Google Scholar